Moderna, Novavax developing combined COVID-19, flu shots – CBC

Novavax, yet to seek approval for its COVID-19 vaccine, is beginning a clinical trial on its combined shot

Sep 09, 2021

Moderna Inc. said on Thursday it was developing a single-dose vaccine that combines a booster dose against COVID-19 and a booster against flu.

“Our number-one priority as a company right now is to bring to market a pan-respiratory annual booster vaccine, which we plan to always customize and upgrade,” chief executive officer Stéphane Bancel said.

The company said the benefits of a pan-respiratory vaccine would be immense, pointing to Centers for Disease Control data that indicates there were over 400,000 hospitalizations due to influenza in the U.S. in the last pre-pandemic year, with the seasonal flu representing an average economic burden of $11 billion US annually.

The drugmaker already had several influenza vaccine candidates in development. The new vaccine combines the experimental flu shot that is furthest along with its COVID-19 vaccine.

Read more: ttps://www.cbc.ca/news/health/moderna-novavax-combined-vaccines-1.6169305

NationTalk Partners & Sponsors Learn More